We harness the power of artificial intelligence and machine learning to predict the presence of cancer earlier.
A multi-dimensional approach to innovation
Over the past 10 years, our team of scientists have used artificial intelligence and machine learning to identify unique and proprietary DNA signatures that predict the presence of cancer as early as stage I. We combined these DNA signatures and protein biomarkers to develop multi-analyte blood tests with greater sensitivity and specificity to current screening modalities.
We focused our technological advances to develop simple, accurate, and customer-friendly tests that detect cancer early—all from a simple blood draw.
The HelioLiver Test is only the beginning
Helio Genomics will launch HelioLiver as the first commercialized test. Liver cancer is the fastest growing and second deadliest cancer worldwide. According to the American Cancer Society, liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time. Studies show that early detection of liver cancer is critical to successful outcomes with a survival rate that is 12 times higher if caught in early versus late stages. These statistics underscore the need for more advanced solutions and therapies for early liver cancer detection.
What’s next for Helio?
Helio’s development pipeline is focused on liver, colon, breast and lung cancer. Our AI-based methods in early cancer detection are based on a robust research and development program leveraging an extensive patient sample bank for validation. Currently, clinical trials for our liver test are underway in the US and China.